AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

Pharmaceutical powerhouse AbbVie(NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Tom Lee, Fundstrat Global Advisors managing partner and head of research, appeared on CNBC to talk about his 2025 playbook.

When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to ...

The global online pharmacy market size was valued at USD 112.46 billion in 2024 and is projected to reach from USD 131.65 billion in 2025 to USD 543.36 billion by 2033 , growing at a CAGR of 17.06% ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Vizient forecasts a 3.84% rise in pharmacy spending for health systems and ambulatory surgery centers, driven by specialty and personalized medicines.

AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...